Results 71 to 80 of about 273,591 (356)
Molecular Oncology, EarlyView.In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková +14 more
wiley +1 more source
Gonadotropin and kisspeptin gene expression, but not GnRH, are impaired in cFOS deficient mice. [PDF]
, 2015 cFOS is a pleiotropic transcription factor, which binds to the AP1 site in the promoter of target genes. In the pituitary gonadotropes, cFOS mediates induction of FSHβ and GnRH receptor genes.
Coss, Djurdjica +3 more
core +1 more source
Molecular Oncology, EarlyView.Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
X-linked agammaglobulinemia and isolated growth hormone deficiency
The Turkish Journal of Pediatrics, 1998 X-linked agammaglobulinemia and isolated growth hormone deficiency was first described in 1980 and then classified as a different primary immune deficiency.
D Arslan +3 more
doaj
The unsolved case of “bone-impairing analgesics”. The endocrine effects of opioids on bone metabolism [PDF]
, 2015 The current literature describes the possible risks for bone fracture in chronic analgesics users. There are three main hypotheses that could explain the increased risk of fracture associated with central analgesics, such as opioids: 1) the increased ...
COLUZZI, FLAMINIA +3 more
core +3 more sources
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
Neurofibromatosis 1 and Growth Hormone Deficiency
Pediatric Neurology Briefs, 2000 The growth profiles and growth hormone levels of children with neurofibromatosis 1 (NF-1) were analyzed at the University of Texas Medical School, Houston, TX.
J Gordon Millichap
doaj +1 more source
Non-alcoholic fatty liver disease connections with fat-free tissues: A focus on bone and skeletal muscle [PDF]
, 2017 The estimates of global incidence and prevalence of non-alcoholic fatty liver disease (NAFLD) are worrisome, due to the parallel burden of obesity and its metabolic complications. Indeed, excess adiposity and insulin resistance represent two of the major
Chiesa, Claudio +4 more
core +2 more sources
Molecular Oncology, EarlyView.This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan +9 more
wiley +1 more source
Vitamin D, a modulator of musculoskeletal health in chronic kidney disease [PDF]
, 2017 The spectrum of activity of vitamin D goes beyond calcium and bone homeostasis, and growing evidence suggests that vitamin D contributes to maintain musculoskeletal health in healthy subjects as well as in patients with chronic kidney disease (CKD ...
Jordi Bover +6 more
core +2 more sources